EN DE
Watch Emergent Biosolutions Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Emergent Biosolutions Inc (EBS) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Emergent Biosolutions Inc stock $18.18, price $6.06, upside +200.0%, quality 67 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

EB Emergent Biosolutions Inc logo Thin data Nov 6, 2026

Emergent Biosolutions Inc

EBS · US
Undervalued, but in a downtrend

The stock costs 67% less than our calculation considers fair.

Fair value $18.18 · Strongly undervalued (67%)
Quality 67/100
Generates free cash flow
Ranks above peers (9/13)
Revenue last quarter +66% vs. a year ago.
Loss over the last twelve months · -23.0% net margin (TTM) · fiscal year 2025 7.1%
Moderate debt
Neutral coverage
Insiders sold $170,992 (6M)
Weak Growth (revenue 5y −14.0 %/yr in USD)
Narrow moat 38/100 · thin data
Thin data
Watch Emergent Biosolutions Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$64.33 $1.50 Fair Value $18.18 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $1.50 – $64.33 · fair‑value band $13.64 – $22.72 · the $6.06 price screens below the $18.18 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.

Follow Emergent Biosolutions in your weekly email

Every Wednesday you see whether Emergent Biosolutions is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally.

Show moreShow less

It operates through Commercial Products, MCM Products, and All Other Revenues segments.

The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination.

It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose.

In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services.

Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Stock analysis

Emergent Biosolutions Inc (EBS) currently trades at $6.06, while our model-based Fair Value estimate is $18.18, implying the stock looks roughly 67% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $33.15 per share, and 21 of the 24 models we run sit above the $6.06 price.

Bear case: the Economic Profit group reads lowest at $6.20, and 3 of the 24 models stay below the price. Data coverage for this calculation is low.

Scenario range: $13.64 (bear) to $22.72 (bull), the price of $6.06 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Emergent Biosolutions Inc reported revenue of $743M in FY2025 versus $1.8B in FY2021, a compound −19.6%/yr. Reported net income was $52.6M in FY2025, compounding −30.0%/yr from FY2021.

Key figures

Market cap $313M Small · P/S ratio 0.43 · EPS (TTM) $−3.22 · Net margin −23.0% · Return on equity −40.3% · Return on assets (EBIT) −6.6% (5-year average) · Operating margin 28.3% · Revenue (TTM) $770M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 56% below its 52-week high and 36% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 200%, EBS screens cheaper than that median.

Fair Value models

Bear $13.64 Fair Value $18.18 Bull $22.72
Price $6.06 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $24.32 $38.76 $57.57 80
Growth DCF $23.94 $36.67 $52.18 78
Owner Earnings $17.30 $28.51 $43.12 75
All 24 models by family
DCF Models
FCF DCF $24.32 $38.76 $57.57 80
Owner Earnings $17.30 $28.51 $43.12 75
5Y Revenue Exit $17.21 $29.36 $44.79 71
5Y EBITDA Exit $27.65 $49.97 $76.80 74
5Y P/E Exit $15.22 $25.45 $36.29 70
10Y Revenue Exit $19.60 $30.53 $45.35 66
10Y EBITDA Exit $25.54 $42.46 $66.15 67
10Y P/E Exit $18.97 $28.26 $39.83 64
Earnings-Based
Graham-Dodd $6.98 $27.83 $37.82 64
Lynch FV $6.91 $9.87 $12.83 61
PEG = 1.0 $6.91 $9.87 $12.83 57
EPV $3.09 $4.21 $5.10 74
Multiples
P/E Multiple $16.93 $22.57 $28.21 63
P/S Multiple $13.08 $17.44 $21.80 58
P/B Multiple $5.67 $7.56 $9.45 55
EV/EBIT $20.25 $29.39 $38.52 65
EV/EBITDA $35.03 $49.10 $63.16 67
EV/Revenue $12.41 $20.79 $29.17 52
Asset-Based
NCAV (Graham) $0.8400 $1.13 $1.68 54
Growth DCF
Growth DCF $23.94 $36.67 $52.18 78
Rev-Margin DCF $17.21 $29.62 $45.00 71
Economic Profit
Residual Income $7.82 $8.18 $9.14 71
ROIC Compounder $3.09 $4.21 $5.10 72
Growth Earnings
Growth-Adj P/E $12.51 $17.87 $23.23 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 67/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 41
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 91
Do the profits arrive as real cash?
Financial strength 28
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 90
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors sold shares worth $170,992 and none bought.

  • SaleDonald W DeGolyerDirector3× since Nov 10, 2025: 51,082 shares, avg. $8.69$443,818Oct 7, 202610b5-1 plan
  • SalePaul Anthony WilliamsSVP, Products Business3× since Apr 1, 2026: 10,000 shares, avg. $7.86$78,550Oct 1, 202610b5-1 plan
  • SaleSujata Tyagi DayalDirector13,761 shares at $8.40$115,610May 1, 202610b5-1 plan
  • SaleKathryn C ZoonDirector17,202 shares at $8.40$144,453May 1, 202610b5-1 plan
  • SaleKeith KatkinDirector15,481 shares at $8.28$128,183Apr 30, 202610b5-1 plan
  • SaleRonald RichardDirector21,984 shares at $11.97$263,101Dec 5, 2025

Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−28.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.0%
Start year 2020 (pandemic). Over 10 years: +4.3% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−23.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−23.4%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−25.6% vs −1.2%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.28% → 15%
Pace: the 5-year rate starts in 2020 (pandemic)

Watch EBS, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (87 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.

Compare Emergent Biosolutions Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 67 · Top 25%
Fair Value upside +200.0% · Top 25%
Profitability
Return on assets 4.0% · Below median
Net margin (12 months) −23.0% · Bottom 25%
Operating margin (12 months) 28.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 66.3% · Top 25%
Balance sheet
Debt / equity 1.10× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.60× · Cheapest 25%
P/S (12 months) 0.41× · Cheapest 25%
Price / free cash flow (fiscal year) 2.0× · Cheapest 25%
EV/EBITDA 2.9× · Cheapest 25%
PEG 0.38× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 15
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)45 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $111.63 +41% vs EBS
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs EBS
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs EBS
Haleon plc HLN $9.14 $8.61 −6% vs EBS
Merck KGaA MRK €148.75 €109.18 −27% vs EBS
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs EBS
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs EBS
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs EBS
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs EBS
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs EBS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Emergent Biosolutions Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Emergent Biosolutions Inc Fair Value". https://www.fairvalue-calculator.com/stock/EBS

Frequently asked questions

Is Emergent Biosolutions Inc (EBS) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $18.18 versus a price of $6.06, about +200% upside (undervalued).
What is the fair value of EBS?
Our model-based fair value for Emergent Biosolutions Inc is $18.18 (as of Nov 6, 2026), built from audited fundamentals. The current price: $6.06.
What is the quality score of EBS?
Emergent Biosolutions Inc has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Emergent Biosolutions Inc (EBS)?
Our model-based price target is the fair value of $18.18 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario $13.64, optimistic scenario $22.72. It is a calculation from audited fundamentals, not an analyst target.
What is the Emergent Biosolutions Inc stock forecast for 2026?
Our models put fair value at $18.18, about +200% upside versus a price of $6.06 (undervalued). Cautious scenario $13.64, optimistic scenario $22.72. The calculation is refreshed regularly with new filings.
What is the revenue of Emergent Biosolutions Inc (EBS)?
Emergent Biosolutions Inc reported trailing-twelve-month revenue of about $770M (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Emergent Biosolutions Inc (EBS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Emergent Biosolutions Inc it is $18.18 per share (as of Nov 6, 2026), against a price of $6.06. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Emergent Biosolutions Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, EBS trades below its calculated fair value: price $6.06, fair value $18.18, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EBS?
No. The price is what the market pays today ($6.06); the fair value is what the company's own numbers justify ($18.18). For Emergent Biosolutions Inc the two are $12.12 per share apart. That gap is exactly why we show both numbers side by side.
How much is Emergent Biosolutions Inc worth?
The market values Emergent Biosolutions Inc at about $313M (market capitalisation, as of Nov 6, 2026). Per share that is $6.06; our models calculate a fair value of $18.18 per share.
What do the bullish and bearish scenarios say about EBS?
Our models span a range for Emergent Biosolutions Inc: cautious scenario $13.64, base $18.18, optimistic $22.72 per share (as of Nov 6, 2026, price $6.06). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of EBS?
The PEG ratio of Emergent Biosolutions Inc is 0.38 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Emergent Biosolutions Inc (EBS)?
Balance-sheet figures for Emergent Biosolutions Inc (as of Nov 6, 2026): return on equity −40.3%, debt of 1.10 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is EBS from its 52-week high?
Emergent Biosolutions Inc trades at $6.06, about 56% below its 52-week high of $13.90 and 36% above the low of $4.45 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $18.18 is for.
Which stocks are comparable to Emergent Biosolutions Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Emergent Biosolutions Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $6.06, calculated fair value $18.18 (+200%), Quality Score 67/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EBS calculated?
We run Emergent Biosolutions Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $18.18 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Emergent Biosolutions Inc currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Emergent Biosolutions Inc (EBS)?
The closing price on Nov 6, 2026 was $6.06. Our model-based fair value is $18.18, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Emergent Biosolutions Inc right now?
The price is below even our cautious bear case ($13.64). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Emergent Biosolutions Inc

How large is the market capitalisation of Emergent Biosolutions Inc (EBS)?
The market capitalisation of Emergent Biosolutions Inc is $313M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Emergent Biosolutions Inc (EBS)?
The price-to-sales ratio of Emergent Biosolutions Inc is 0.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Emergent Biosolutions Inc (EBS)?
Earnings per share at Emergent Biosolutions Inc are $−3.22. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Emergent Biosolutions Inc (EBS)?
The net margin of Emergent Biosolutions Inc is −23.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Emergent Biosolutions Inc (EBS)?
The return on equity (ROE) of Emergent Biosolutions Inc is −40.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Emergent Biosolutions Inc (EBS)?
On an EBIT basis the return on assets of Emergent Biosolutions Inc is −6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Emergent Biosolutions Inc (EBS)?
The operating margin of Emergent Biosolutions Inc is 28.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Emergent Biosolutions Inc (EBS)?
Revenue at Emergent Biosolutions Inc is growing +66.3% versus a year earlier (3y avg −12.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Emergent Biosolutions Inc (EBS)?
Earnings per share at Emergent Biosolutions Inc are growing −93.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Emergent Biosolutions Inc (EBS) generate?
The free cash flow of Emergent Biosolutions Inc is $157M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Emergent Biosolutions Inc (EBS) carry?
The net debt of Emergent Biosolutions Inc is $367M (fiscal year 2025, ≈ 2.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Emergent Biosolutions Inc in the live analysis

One click puts Emergent Biosolutions Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.